Xeris Biopharma Holdings Insider Kevin McCulloch Sells $312K of Stock
Kevin McCulloch sold 25,000 shares of Xeris Biopharma Holdings, Inc. at $12.49 a share, worth $312K in total on Nov 5, 2026. Shares held after the trade: 1,559,208 (-1.6%).
Xeris Biopharma reported a significant increase in total revenue to $107.2 million for the third quarter of 2026, up from $74.4 million in the prior year. While the company achieved a net income of $11.3 million for the quarter, it recorded a net loss of $17.6 million for the nine-month period, largely driven by a $30.8 million loss on debt extinguishment.
Xeris Biopharma delivered a strong Q3 with 44% revenue growth, significantly raising 2030 revenue targets to over $1 billion driven by Recorlev momentum.
Xeris Biopharma reported third quarter 2026 total revenue of $107.2 million, a 44% increase year-over-year, driven primarily by a 93% surge in Recorlev net revenue. The company achieved net income of $11.3 million and raised its full-year 2026 revenue guidance to a range of $395 million to $405 million.
“As a biopharmaceutical leader in endocrine and rare diseases, our strong third quarter performance puts us on a new growth curve that is accelerating our Company’s near-term outlook, and we are now on a path to reach more than $1 billion in total revenue in 2030.”
John Shannon, Chairman and Chief Executive Officer
“We now see Recorlev on a path to nearly $1 billion in annual net revenue three to four years sooner than previously expected.”
John Shannon, Chairman and Chief Executive Officer
Xeris Biopharma Holdings Insider Steven Pieper Sells $51.2K of Stock
Steven Pieper sold 5,000 shares of Xeris Biopharma Holdings, Inc. at $10.23 a share, worth $51.2K in total on Nov 2, 2026. Shares held after the trade: 1,346,053 (-0.4%).
Xeris Biopharma Holdings Insider Beth Hecht Sells $256K of Stock
Beth Hecht sold 25,000 shares of Xeris Biopharma Holdings, Inc. at $10.23 a share, worth $256K in total on Nov 2, 2026. Shares held after the trade: 1,086,130 (-2.2%).
Xeris Biopharma Holdings Insider Kevin McCulloch Sells $153K of Stock
Kevin McCulloch sold 15,000 shares of Xeris Biopharma Holdings, Inc. at $10.23 a share, worth $153K in total on Nov 2, 2026. Shares held after the trade: 1,584,208 (-0.9%).
Xeris Biopharma Holdings appointed Menassie Taddese to its Board of Directors and Audit Committee, effective November 2, 2026. In connection with his appointment, Mr. Taddese received an initial equity award of options and RSUs with a grant date fair value of approximately $450,000 and will be eligible for annual equity grants of $300,000. Mr. Taddese brings nearly 30 years of experience from leadership roles at Viatris and Pfizer.